Oct 16, 2026 This Week in Cardiology Podcast
Unable to add items
Add to basket failed.
Add to wishlist failed.
Failed to remove from Wish List.
Adding to library failed
Unable to follow podcast
Unable to unfollow podcast
Oct 16, 2026 This Week in Cardiology Podcast
-
Narrated by:
-
By:
Some promising studies in amyloidosis, aficamten in nonobstructive HCM, costs of the microaxial flow pump in cardiogenic shock, and more on the VESALIUS trial of evolocumab are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Light Chain Amyloidosis – A Potentially Helpful Drug
Anselamimab Does Not Reduce Light-Chain Amyloidosis Deaths
https://www.medscape.com/viewarticle/anselamimab-does-not-reduce-light-chain-amyloidosis-deaths-2026a1000z79
II Aficamten in Nonobstructive HCM: The ACACIA trial
III Microaxial Flow Pump Cost Analysis of Danger Shock
IV More on Evolocumab at ESC: Vesalius Trial Substudies
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
https://www.medscape.com/viewarticle/1003092
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.